Yet, as impressive as those results are, an investor's returns still would have lagged the even-more-substantial business results of the company. The reasoning is relatively straightforward: Teva's stock price has abandoned its once "normal" P/E around 20, sunk past a reasonable market P/E of 15, bypassed a "new normal" P/E around 13 in the last five years and has compressed all the way down to today's P/E of 8.5. In viewing the earnings-and-price-correlated graph below, one can clearly see Teva's stock price and the company's earnings power becoming disconnected. In turn, one of two things is happening: First, if the fundamentals of the company remain intact, this could be signaling an unjust reaction in the market. On the other hand, if the business behind the stock begins to falter, this could indicate a balanced view on discounting lower future earnings. So the question is not,"Was Teva a strong company?" but, more aptly, "Will Teva continue to grow in the future?" To be honest, the answer isn't perfectly clear or straightforward, but there is some indication that the current undervaluation of Teva might be a touch overblown. First and foremost, Teva isn't a one-trick pony. Although roughly half of its profits are derived from treating multiple sclerosis, Teva makes about a quarter of its money from global generics, about 20% from other specialty brands and about 5% from over-the-counter products. Much of the low valuation is likely a resultant of Copaxone -- the world's leading MS treatment -- coming off patent sooner rather than later. But there are two mitigating factors that suggest Teva won't lose half its earnings overnight. For one, much in the same manner that people still buy Johnson & Johnson's ( JNJ) Listerine instead of the generic, it's not as if your profits go to zero as soon as the patent expires. But more important, the complications associated with both creating and getting approval for the drug would likely inhibit widespread generic competition. As a corollary to the expiration of patents, Teva is in the generic business as well. So while the pharmaceutical business might suffer to a degree on the branded MS treatment side, it would concurrently benefit from the bevy of patents to expire in the coming years. Given Teva's size, geographic scope and ability to deal in complex drugs, the company appears well-positioned in this regard. In addition, Teva's management has indicated its enthusiasm for two additional business catalysts -- a quick-growing emerging market and its OTC partnerships. Within emerging markets, Teva estimates the pharmaceutical demand for the emerging population will double in the next five years. With regard to the OTC partnership, Teva has strategically aligned itself with Procter & Gamble ( PG) to offer products such as Vick's in over 20 countries. Said differently, while the pharmaceutical business faces obstacles in the near term, the underlying future appears bright for those that can position themselves appropriately to provide global health assistance. In viewing the Estimated Earnings and Return Calculator from F.A.S.T. Graphs, we see this picture being painted for Teva's stock price as well. Based on the consensus estimates of 27 analysts reporting to S&P -- along with a 3% long-term earnings growth rate and constant dividend payout ratio -- the calculator comes to an annualized total return number of roughly 18% over a five-year holding period. But it's important to understand the limits behind the calculator. For example, just a few years ago it certainly wouldn't have been unreasonable to assume a price to earnings ratio around 15. Today it might be wise to assume a slightly lower rate. In turn, the expected earnings and growth rate appear sensible. Zack's comes to a higher consensus growth rate while Value Line predicts the same 3% intermediate-term rate that F.A.S.T Graphs shows. Given that Teva provided normalized earnings guidance in the $4.85-$5.15 range for fiscal year 2013, the default estimates appear to be within a reasonable range. Interestingly, even a P/E around 10 in half a decade would equate to price appreciation of almost 10% -- and that's without considering the dividend, which has the potential to grow faster than earnings due to Teva's low payout ratio. Overall, Teva Pharmaceuticals appears to be a very strong company that faces some near-term challenges. To alleviate these concerns, the Israel-based drug corporation has a geographic footprint that seems to be well-positioned in a variety of areas. Especially appealing is that Teva doesn't have to do anything all that spectacular -- 3% growth for the next five years for example -- to provide above-average returns. Although it is always prudent to be on the look-out for a declining business, Teva's commitment to rewarding shareholders provides an exciting avenue for further due diligence. At the time of publication, the author was long TEVA.This article was written by an independent contributor, separate from TheStreet's regular news coverage.